Hyperthermic Isolated Perfusion with Tumor Necrosis Factor-alpha and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcoma: The Experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)
Background: Tumor necrosis factor-alpha (TNFα)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFα dosages. After a phase I-II study, the SITILO (Italian...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2009-03, Vol.23 (2), p.363 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 363 |
| container_title | In vivo (Athens) |
| container_volume | 23 |
| creator | Di Filippo, F Giacomini, P Rossi, C R Santinami, M Garinei, R Anzà, M Deraco, M Botti, C Perri, P Cavaliere, F Di Angelo, P Sofra, C Sperduti, I Pasqualoni, R Di Filippo, S Corrias, F Armenti, A Ferraresi, V |
| description | Background: Tumor necrosis factor-alpha (TNFα)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out
at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFα
dosages. After a phase I-II study, the SITILO (Italian Society of Integrated Locoregional Therapies in Oncology) centers began
to employ the lower dose of 1 mg of TNFα. The aim of this paper is to report on the results obtained in 75 patients with limb-threatening
STS treated with a low TNFα dose and doxorubicin (Dx). Patients and Methods: HILP with TNFα (at a dosage of either â¤1 mg or
>1 mg) and Dx was administered to 75 patients with limb-threatening STS: 37 males and 38 females; median age 50 years; tumor
in the lower and upper limbs in 58 and 17 patients, respectively; primary and recurrent tumors in 45 and 30 patients, respectively.
Most tumors (77%) were high grade. Tumor resection was carried out 6 to 8 weeks after HILP. Results: The grade of limb toxicity
was mild to moderate in the vast majority of patients (76%). Grades IV and V were observed, but only when high muscle temperatures
were recorded and high TNFα dosages were employed. Systemic toxicity was also mild to moderate and there were no postoperative
deaths. Complete and partial tumor responses were 34% and 48%, respectively, with an overall response of 82% . Limb sparing
surgery was carried out in 85.3% of patients. At a median follow-up of 28 months, 16 recurrences (21.3%) were recorded, with
a 5-year locoregional disease-free survival of 63% . The 5-year disease-free survival and overall survival were 36.7% and
61.6%, respectively. Conclusion: HILP with 1 mg of TNFα is an effective neoadjuvant therapy resulting in a high rate of limb
sparing in limb-threatening STS, with acceptable local reactions and negligible systemic toxicity. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_highw</sourceid><recordid>TN_cdi_pubmed_primary_19414428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19414428</sourcerecordid><originalsourceid>FETCH-LOGICAL-h238t-fb88e3646b4e7a129801ae4ca0f97e708f940edda6488e8eed4d16cb442d7b0f3</originalsourceid><addsrcrecordid>eNpNkM1q3DAUhU1paCZpXyFo0UWzMMi2xpazC2l-DCYTGBe6M9fyla1gS4MkJ5lnzktE0zSQ1YXDd849nC_RKinKJC7WrPwarWi65jFfJ3-PoxPnHinNC0rTb9FxUrKEsZSvote7_Q6tH9HOSpDKmQk89uQBrVycMpo8Kz-SZpmNJfcorHHKkRsQ3tgYpt0IBHRPfpsXY5dOCaWJDGTII41F8DNqT4wktZq7uBkPEmqlB7I10pNGObcg2YIVZoYL0gTb9Uvoo1ALPPgOQZWHSYEOFqHQ7w9ypT0O9l_T2ghjcQhVYfr0MxTZaGEmM-zJr23VVPXm_Ht0JGFy-OP_PY3-3Fw3V3dxvbmtri7reEwz7mPZcY5ZzvKOYQFJWnKaADIBVJYFFpTLklHse8hZADliz_okF10YtC86KrPT6Ow9d7d0M_btzqoZ7L79WD0AP9-BUQ3js7LYuhmmKeBZq57SrE3bLM-yN54ikbU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hyperthermic Isolated Perfusion with Tumor Necrosis Factor-alpha and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcoma: The Experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Di Filippo, F ; Giacomini, P ; Rossi, C R ; Santinami, M ; Garinei, R ; Anzà, M ; Deraco, M ; Botti, C ; Perri, P ; Cavaliere, F ; Di Angelo, P ; Sofra, C ; Sperduti, I ; Pasqualoni, R ; Di Filippo, S ; Corrias, F ; Armenti, A ; Ferraresi, V</creator><creatorcontrib>Di Filippo, F ; Giacomini, P ; Rossi, C R ; Santinami, M ; Garinei, R ; Anzà, M ; Deraco, M ; Botti, C ; Perri, P ; Cavaliere, F ; Di Angelo, P ; Sofra, C ; Sperduti, I ; Pasqualoni, R ; Di Filippo, S ; Corrias, F ; Armenti, A ; Ferraresi, V</creatorcontrib><description>Background: Tumor necrosis factor-alpha (TNFα)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out
at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFα
dosages. After a phase I-II study, the SITILO (Italian Society of Integrated Locoregional Therapies in Oncology) centers began
to employ the lower dose of 1 mg of TNFα. The aim of this paper is to report on the results obtained in 75 patients with limb-threatening
STS treated with a low TNFα dose and doxorubicin (Dx). Patients and Methods: HILP with TNFα (at a dosage of either â¤1 mg or
>1 mg) and Dx was administered to 75 patients with limb-threatening STS: 37 males and 38 females; median age 50 years; tumor
in the lower and upper limbs in 58 and 17 patients, respectively; primary and recurrent tumors in 45 and 30 patients, respectively.
Most tumors (77%) were high grade. Tumor resection was carried out 6 to 8 weeks after HILP. Results: The grade of limb toxicity
was mild to moderate in the vast majority of patients (76%). Grades IV and V were observed, but only when high muscle temperatures
were recorded and high TNFα dosages were employed. Systemic toxicity was also mild to moderate and there were no postoperative
deaths. Complete and partial tumor responses were 34% and 48%, respectively, with an overall response of 82% . Limb sparing
surgery was carried out in 85.3% of patients. At a median follow-up of 28 months, 16 recurrences (21.3%) were recorded, with
a 5-year locoregional disease-free survival of 63% . The 5-year disease-free survival and overall survival were 36.7% and
61.6%, respectively. Conclusion: HILP with 1 mg of TNFα is an effective neoadjuvant therapy resulting in a high rate of limb
sparing in limb-threatening STS, with acceptable local reactions and negligible systemic toxicity.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>PMID: 19414428</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Chemotherapy, Cancer, Regional Perfusion - methods ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Extremities - pathology ; Female ; Humans ; Hyperthermia, Induced ; Male ; Middle Aged ; Perfusion ; Recurrence ; Sarcoma - drug therapy ; Soft Tissue Neoplasms - drug therapy ; Treatment Outcome ; Tumor Necrosis Factor-alpha - administration & dosage</subject><ispartof>In vivo (Athens), 2009-03, Vol.23 (2), p.363</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19414428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Filippo, F</creatorcontrib><creatorcontrib>Giacomini, P</creatorcontrib><creatorcontrib>Rossi, C R</creatorcontrib><creatorcontrib>Santinami, M</creatorcontrib><creatorcontrib>Garinei, R</creatorcontrib><creatorcontrib>Anzà, M</creatorcontrib><creatorcontrib>Deraco, M</creatorcontrib><creatorcontrib>Botti, C</creatorcontrib><creatorcontrib>Perri, P</creatorcontrib><creatorcontrib>Cavaliere, F</creatorcontrib><creatorcontrib>Di Angelo, P</creatorcontrib><creatorcontrib>Sofra, C</creatorcontrib><creatorcontrib>Sperduti, I</creatorcontrib><creatorcontrib>Pasqualoni, R</creatorcontrib><creatorcontrib>Di Filippo, S</creatorcontrib><creatorcontrib>Corrias, F</creatorcontrib><creatorcontrib>Armenti, A</creatorcontrib><creatorcontrib>Ferraresi, V</creatorcontrib><title>Hyperthermic Isolated Perfusion with Tumor Necrosis Factor-alpha and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcoma: The Experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>Background: Tumor necrosis factor-alpha (TNFα)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out
at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFα
dosages. After a phase I-II study, the SITILO (Italian Society of Integrated Locoregional Therapies in Oncology) centers began
to employ the lower dose of 1 mg of TNFα. The aim of this paper is to report on the results obtained in 75 patients with limb-threatening
STS treated with a low TNFα dose and doxorubicin (Dx). Patients and Methods: HILP with TNFα (at a dosage of either â¤1 mg or
>1 mg) and Dx was administered to 75 patients with limb-threatening STS: 37 males and 38 females; median age 50 years; tumor
in the lower and upper limbs in 58 and 17 patients, respectively; primary and recurrent tumors in 45 and 30 patients, respectively.
Most tumors (77%) were high grade. Tumor resection was carried out 6 to 8 weeks after HILP. Results: The grade of limb toxicity
was mild to moderate in the vast majority of patients (76%). Grades IV and V were observed, but only when high muscle temperatures
were recorded and high TNFα dosages were employed. Systemic toxicity was also mild to moderate and there were no postoperative
deaths. Complete and partial tumor responses were 34% and 48%, respectively, with an overall response of 82% . Limb sparing
surgery was carried out in 85.3% of patients. At a median follow-up of 28 months, 16 recurrences (21.3%) were recorded, with
a 5-year locoregional disease-free survival of 63% . The 5-year disease-free survival and overall survival were 36.7% and
61.6%, respectively. Conclusion: HILP with 1 mg of TNFα is an effective neoadjuvant therapy resulting in a high rate of limb
sparing in limb-threatening STS, with acceptable local reactions and negligible systemic toxicity.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Chemotherapy, Cancer, Regional Perfusion - methods</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Extremities - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperthermia, Induced</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Perfusion</subject><subject>Recurrence</subject><subject>Sarcoma - drug therapy</subject><subject>Soft Tissue Neoplasms - drug therapy</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - administration & dosage</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM1q3DAUhU1paCZpXyFo0UWzMMi2xpazC2l-DCYTGBe6M9fyla1gS4MkJ5lnzktE0zSQ1YXDd849nC_RKinKJC7WrPwarWi65jFfJ3-PoxPnHinNC0rTb9FxUrKEsZSvote7_Q6tH9HOSpDKmQk89uQBrVycMpo8Kz-SZpmNJfcorHHKkRsQ3tgYpt0IBHRPfpsXY5dOCaWJDGTII41F8DNqT4wktZq7uBkPEmqlB7I10pNGObcg2YIVZoYL0gTb9Uvoo1ALPPgOQZWHSYEOFqHQ7w9ypT0O9l_T2ghjcQhVYfr0MxTZaGEmM-zJr23VVPXm_Ht0JGFy-OP_PY3-3Fw3V3dxvbmtri7reEwz7mPZcY5ZzvKOYQFJWnKaADIBVJYFFpTLklHse8hZADliz_okF10YtC86KrPT6Ow9d7d0M_btzqoZ7L79WD0AP9-BUQ3js7LYuhmmKeBZq57SrE3bLM-yN54ikbU</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Di Filippo, F</creator><creator>Giacomini, P</creator><creator>Rossi, C R</creator><creator>Santinami, M</creator><creator>Garinei, R</creator><creator>Anzà, M</creator><creator>Deraco, M</creator><creator>Botti, C</creator><creator>Perri, P</creator><creator>Cavaliere, F</creator><creator>Di Angelo, P</creator><creator>Sofra, C</creator><creator>Sperduti, I</creator><creator>Pasqualoni, R</creator><creator>Di Filippo, S</creator><creator>Corrias, F</creator><creator>Armenti, A</creator><creator>Ferraresi, V</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20090301</creationdate><title>Hyperthermic Isolated Perfusion with Tumor Necrosis Factor-alpha and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcoma: The Experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)</title><author>Di Filippo, F ; Giacomini, P ; Rossi, C R ; Santinami, M ; Garinei, R ; Anzà, M ; Deraco, M ; Botti, C ; Perri, P ; Cavaliere, F ; Di Angelo, P ; Sofra, C ; Sperduti, I ; Pasqualoni, R ; Di Filippo, S ; Corrias, F ; Armenti, A ; Ferraresi, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h238t-fb88e3646b4e7a129801ae4ca0f97e708f940edda6488e8eed4d16cb442d7b0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Chemotherapy, Cancer, Regional Perfusion - methods</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Extremities - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperthermia, Induced</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Perfusion</topic><topic>Recurrence</topic><topic>Sarcoma - drug therapy</topic><topic>Soft Tissue Neoplasms - drug therapy</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Filippo, F</creatorcontrib><creatorcontrib>Giacomini, P</creatorcontrib><creatorcontrib>Rossi, C R</creatorcontrib><creatorcontrib>Santinami, M</creatorcontrib><creatorcontrib>Garinei, R</creatorcontrib><creatorcontrib>Anzà, M</creatorcontrib><creatorcontrib>Deraco, M</creatorcontrib><creatorcontrib>Botti, C</creatorcontrib><creatorcontrib>Perri, P</creatorcontrib><creatorcontrib>Cavaliere, F</creatorcontrib><creatorcontrib>Di Angelo, P</creatorcontrib><creatorcontrib>Sofra, C</creatorcontrib><creatorcontrib>Sperduti, I</creatorcontrib><creatorcontrib>Pasqualoni, R</creatorcontrib><creatorcontrib>Di Filippo, S</creatorcontrib><creatorcontrib>Corrias, F</creatorcontrib><creatorcontrib>Armenti, A</creatorcontrib><creatorcontrib>Ferraresi, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Filippo, F</au><au>Giacomini, P</au><au>Rossi, C R</au><au>Santinami, M</au><au>Garinei, R</au><au>Anzà, M</au><au>Deraco, M</au><au>Botti, C</au><au>Perri, P</au><au>Cavaliere, F</au><au>Di Angelo, P</au><au>Sofra, C</au><au>Sperduti, I</au><au>Pasqualoni, R</au><au>Di Filippo, S</au><au>Corrias, F</au><au>Armenti, A</au><au>Ferraresi, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperthermic Isolated Perfusion with Tumor Necrosis Factor-alpha and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcoma: The Experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>23</volume><issue>2</issue><spage>363</spage><pages>363-</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>Background: Tumor necrosis factor-alpha (TNFα)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out
at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFα
dosages. After a phase I-II study, the SITILO (Italian Society of Integrated Locoregional Therapies in Oncology) centers began
to employ the lower dose of 1 mg of TNFα. The aim of this paper is to report on the results obtained in 75 patients with limb-threatening
STS treated with a low TNFα dose and doxorubicin (Dx). Patients and Methods: HILP with TNFα (at a dosage of either â¤1 mg or
>1 mg) and Dx was administered to 75 patients with limb-threatening STS: 37 males and 38 females; median age 50 years; tumor
in the lower and upper limbs in 58 and 17 patients, respectively; primary and recurrent tumors in 45 and 30 patients, respectively.
Most tumors (77%) were high grade. Tumor resection was carried out 6 to 8 weeks after HILP. Results: The grade of limb toxicity
was mild to moderate in the vast majority of patients (76%). Grades IV and V were observed, but only when high muscle temperatures
were recorded and high TNFα dosages were employed. Systemic toxicity was also mild to moderate and there were no postoperative
deaths. Complete and partial tumor responses were 34% and 48%, respectively, with an overall response of 82% . Limb sparing
surgery was carried out in 85.3% of patients. At a median follow-up of 28 months, 16 recurrences (21.3%) were recorded, with
a 5-year locoregional disease-free survival of 63% . The 5-year disease-free survival and overall survival were 36.7% and
61.6%, respectively. Conclusion: HILP with 1 mg of TNFα is an effective neoadjuvant therapy resulting in a high rate of limb
sparing in limb-threatening STS, with acceptable local reactions and negligible systemic toxicity.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>19414428</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2009-03, Vol.23 (2), p.363 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmed_primary_19414428 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Chemotherapy, Cancer, Regional Perfusion - methods Disease-Free Survival Doxorubicin - administration & dosage Extremities - pathology Female Humans Hyperthermia, Induced Male Middle Aged Perfusion Recurrence Sarcoma - drug therapy Soft Tissue Neoplasms - drug therapy Treatment Outcome Tumor Necrosis Factor-alpha - administration & dosage |
| title | Hyperthermic Isolated Perfusion with Tumor Necrosis Factor-alpha and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcoma: The Experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T08%3A56%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperthermic%20Isolated%20Perfusion%20with%20Tumor%20Necrosis%20Factor-alpha%20and%20Doxorubicin%20for%20the%20Treatment%20of%20Limb-Threatening%20Soft%20Tissue%20Sarcoma:%20The%20Experience%20of%20the%20Italian%20Society%20of%20Integrated%20Locoregional%20Treatment%20in%20Oncology%20(SITILO)&rft.jtitle=In%20vivo%20(Athens)&rft.au=Di%20Filippo,%20F&rft.date=2009-03-01&rft.volume=23&rft.issue=2&rft.spage=363&rft.pages=363-&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/&rft_dat=%3Cpubmed_highw%3E19414428%3C/pubmed_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19414428&rfr_iscdi=true |